Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease
Pathogens · 2025
DOI: 10.3390/pathogens14040322 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, 2025. Verfasst von Sanctus Musafiri und 8 weiteren Autor:innen. Beteiligte Einrichtung: University Teaching Hospital of Kigali (CHUK), Kigali KN 4 Ave, Rwanda. Hauptthemen laut MEDLINE: Antiviral Agents, Marburg Virus Disease, Marburgvirus. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
During the current outbreak of Marburg virus disease (MVD) in Rwanda, we synthesized evidence from the literature to improve case management. Accordingly, experimental treatment was offered to patients under close follow-up. Remdesivir alone or in combination with monoclonal antibody treatment (MBP091) complemented with supportive care has improved the clinical outcomes of patients. Additionally, we have identified several experimental therapies currently under investigation, including antiviral drugs such as favipiravir, galidesivir, obeldesivir, and remdesivir, along with monoclonal and polyclonal antibodies (e.g., polyclonal IgG, monoclonal antibody MR-78-N; MR82-N; MR191-N; monoclonal antibodies MR186-YTE and MBP091). Furthermore, substantial progress is being made in vaccine development, with promising candidates including adenovirus-vectored vaccines, DNA vaccines, and the recombinant vesicular stomatitis virus (rVSV) vaccine. Moreover, innovative preventive and treatment strategies—such as synthetic hormones like estradiol benzoate, small interfering RNA (siRNA), interferon-β therapy, and phosphorodiamidate morpholino oligomers—are emerging as potential options for MVD management. Further investment is needed to accelerate research and optimize these therapeutics and preventive modalities. Additional epidemiological, preclinical, and clinical studies are warranted to generate the evidence required to inform policymaking, resource mobilization, and the implementation of cost-effective interventions for the prevention, control, and treatment of MVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Teaching Hospital of Kigali (CHUK), Kigali KN 4 Ave, Rwanda.
- School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Kigali 3900, Rwanda.
- Rwanda Biomedical Centre, Kigali 7162, Rwanda.
- Department of Pediatrics, King Faisal Hospital, Kigali 20093, Rwanda.
- Department of Clinical Service, Ministry of Health, Kigali 84, Rwanda.
- King Faisal Hospital, Kigali 20093, Rwanda.
ORCID-Profile: Emmanuel Edwar Siddig, John Baptist Nkuranga, Ayman Ahmed, Claude Mambo Muvunyi
Zitieren
APA
Musafiri, S., Siddig, E. E., Nkuranga, J. B., Rukundo, A., Mpunga, T., Sendegeya, A., Twagirumugabe, T., Ahmed, A., & Muvunyi, C. M. (2025). Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease. Pathogens. https://doi.org/10.3390/pathogens14040322
Vancouver
Musafiri S, Siddig EE, Nkuranga JB, Rukundo A, Mpunga T, Sendegeya A, et al. Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease. Pathogens. 2025. doi:10.3390/pathogens14040322
BibTeX
@article{Musafiri2025,
author = {Musafiri, Sanctus and Siddig, Emmanuel Edwar and Nkuranga, John Baptist and Rukundo, Athanase and Mpunga, Tharcisse and Sendegeya, Augustin and Twagirumugabe, Theogene and Ahmed, Ayman and Muvunyi, Claude Mambo},
title = {Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14040322}
}
EUVIMED